The NHS stands to gain £23 million as part of a proposed resolution by Vifor Pharma following a Competition and Markets Authority (CMA) investigation into allegations of misleading claims about a rival iron deficiency treatment, the agency has announced today (10 December).
The CMA’s investigation focused on whether Vifor Pharma, maker of Ferinject, restricted competition by spreading misleading information about the safety of Monofer, a competing intravenous iron treatment by Pharmacosmos. The treatments are vital for patients who cannot use oral medications, such as those with long-term conditions or requiring surgery.
To address these concerns, Vifor Pharma has offered several commitments:
- A £23 million payment to healthcare systems across the UK.
- Corrective communications to healthcare professionals about Ferinject and Monofer.
- New measures to prevent the spread of misleading information in the future.
These commitments, currently under consultation, aim to protect patients, support competition, and ensure the NHS receives value for money.
Consultation Details
The CMA is inviting views on these commitments, which would become legally binding if accepted. The consultation closes on January 17, 2025. Feedback can be emailed to 51377-consultation@cma.gov.uk.
This resolution marks a first for the CMA in addressing misleading claims under competition law. Juliette Enser, Executive Director for Competition Enforcement at the CMA, highlighted the importance of accurate claims in healthcare:
“Pharmaceutical companies must think carefully when making claims about competitors. These can have real impacts on healthcare professionals’ decisions and patients’ lives.”
Background
The investigation began in January 2024 under the Competition Act 1998, focusing on potential abuse of a dominant position. Since 2020, the CMA has taken several actions in the pharmaceutical sector, delivering significant savings for the NHS, including fines totaling around £400 million.
For more information, visit the Vifor Pharma investigation page on the CMA website.
and here: https://www.gov.uk/government/news/nhs-set-to-benefit-from-23-million-following-cma-pharma-probe
